Briefing.com uses cookies to store information on your computer that is essential to making the site work and to customizing the user experience. By using the site, you consent to the placement of these cookies. Read our cookie policy to learn more and how to withdraw your consent.     
You must subscribe to access archives older
than one year.
Take a free trial of Briefing In Play® now.
Subscribe Here
TERMS OF USE

The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.com’s RSS service. The use of the RSS service is also subject to the terms and conditions of the Briefing.com Reader Agreement which governs the use of Briefing.com's entire web site (www.briefing.com) including all information services. These Terms of Use and the Briefing.com Reader Agreement may be changed by Briefing.com at any time without notice.

Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for use by individuals, as long as the feeds are used for such individual’s personal, non-commercial use. Any other uses, including without limitation the incorporation of advertising into or the placement of advertising associated with or targeted towards the RSS Content, are strictly prohibited. You are required to use the RSS feeds as provided by Briefing.com and you may not edit or modify the text, content or links supplied by Briefing.com. To acquire more extensive licensing rights to Briefing.com content please review this page.

Link to Content Pages:
The RSS service may be used only with those platforms from which a functional link is made available that, when accessed, takes the viewer directly to the display of the full article on the Briefing.com web site. You may not display the RSS content in a manner that does not permit successful linking to, redirection to or delivery of the applicable Briefing.com web site page. You may not insert any intermediate page, “splash” page or any other content between the RSS link and the applicable Briefing.com web site page.

Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS content, and any and all Briefing.com logos and trademarks used in connection with the RSS service. You are required to provide appropriate attribution to the Briefing.com web site in connection with your use of the RSS feeds. If you provide this attribution using a graphic we require you to use the Briefing.com web site logo that we have incorporated into the Briefing.com RSS feed.

Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any or all of the RSS feeds at any time and to require you to cease displaying, distributing or otherwise using any or all of the RSS feeds for any reason including, without limitation, your violation of any provision of these Terms of Use or the terms and conditions of the Briefing.com Reader Agreement. Briefing.com assumes no liability for any of your activities in connection with the RSS feeds or for your use of the RSS feeds in connection with your web site.

Briefing.com
Subscribers Log In
 
  • HOME
  • OUR VIEW
    • Page One
    • The Big Picture
  • ANALYSIS
    • Premium Analysis
    • Story Stocks
  • MARKETS
    • Stock Market Update
    • Bond Market Update
    • Market Internals
    • After Hours Report
    • Weekly Wrap
  • CALENDARS
    • Upgrades/Downgrades
    • Economic
    • Stock Splits
    • IPO
    • Earnings
    • Conference Calls
    • Earnings Guidance
  • EMAILS
    • Edit My Profile
  • LEARNING CENTER
    • About Briefing.com
    • Ask An Analyst
    • Analysis
    • General Concepts
    • Strategies
    • Resources
    • Video
  • COMMUNITY
    • Twitter
    • Facebook
    • LinkedIn
    • YouTube
    • Google+
  • SEARCH
Login | Archive | EmailEmail |
HOME > Analysis >Story Stocks >Analysts' Outlook on Elanco...
Story Stocks® Archive
Last Update: 15-Oct-18 09:41 ET
Analysts' Outlook on Elanco Animal Health Varied as Quiet Period Expires (ELAN)

Today, the quiet period for Eli Lilly spin-off Elanco Animal Health (ELAN 32.01, -0.57, -1.75%) expired, allowing firms involved with its IPO to publish research and estimates on the stock for the first time. As some may recall, its IPO was quite successful, pricing above the expected price range ($24 vs. $20-$23) and opening for trading with a sizable 34% opening pop. Investors were clearly enthusiastic about the deal, which was underwritten and marketed by blue chip investment banking firms Goldman Sachs, JP Morgan, and Morgan Stanley. Although its top-line growth isn't spectacular, its strong market position, profitability and cash flow generation made it an attractive option for investors.

However, with the stock up 36% from its IPO price, it seems analysts aren't quite as enthusiastic as investors were back when ELAN went public on September 20. Overall, initiations today came in mixed, with analysts generally not expecting significant upside from here, based on their price targets.

With a 1-Year Forward P/E north of 35x, and modest growth expected, analysts are likely seeing the stock as fairly valued at current prices. ELAN does have its Q3 earnings report coming up soon on November 6 and if the company manages to outperform expectations, sentiment in the analyst community could shift quickly.

For the time being, though, today's quiet period expiration doesn't provide much of a spark for ELAN shares, which have cooled off since its hot start.

ELAN Overview

ELAN, which was spun off from Eli Lilly (LLY), is an animal health company that makes health products for companion and food animals. Elanco is the fourth largest animal health company in the world, with revenue of $2.9 bln last year. Globally, Elanco is #1 in medicinal feed additives, #2 in poultry and #3 in cattle. It also has one of the broadest portfolios of pet parasiticides in the companion animal sector.

Elanco offers a diverse portfolio of more than 125 brands. Its vision is to enrich the lives of people through food (making protein more accessible and affordable) and through pet companionship (helping pets live longer, healthier lives). The food animal sector focuses on species raised to provide animal protein, such as cattle, other ruminants (sheep and goats), swine, poultry and aqua.

Over the past 10 years, ELAN has transformed itself from a food animal focused company into a diversified global company. In addition to its FA Ruminants & Swine category, ELAN now has established positions in three targeted growth categories: CA Disease Prevention, CA Therapeutics and FA Future Protein & Health.

Recent acquisitions include the animal health business of Janssen Pharmaceutica (a subsidiary of J&J), ChemGen, Lohmann, the animal health business of Novartis AG and the US feline and canine vaccines portfolio of BI Vetmedica. As a result of these acquisitions as well as organic growth, ELAN has grown its companion animal categories, from a minimal presence in 2007 to more than $900 mln in revenue in 2017.

The company is profitable on a non-GAAP basis. However, revenue growth is pretty modest. In 2017, pro forma revenue declined 1% to $2.89 bln. In 1H18, revenue grew 4.8% yr/yr to $1.51 bln. Adjusted EBITDA on a pro forma basis was $498.9 mln in 2017. In 1H18, adjusted EBITDA rose 10% yr/yr to $306.2 mln. Elanco also plans to pay a small quarterly dividend of $0.06/share.

Quiet Period Expiration

There was a flurry of activity this morning from analysts as the quiet period expired. This is not unusual because the more substantial the IPO, the more investment banks there will be involved. The big three that are probably garnering the most attention are Goldman Sachs, Morgan Stanley, and JP Morgan's initiations.

Both Goldman and Morgan Stanley took a more cautious approach, going with a Neutral ($30 price target), and Equal-Weight ($35) price target, respectively. Goldman's $30 price target, which is 8% below current prices, certainly stands out. On the other hand, JP Morgan was one of the more bullish firms out there this morning, assigning an Overweight and $38 price target.

A few other notable initiations include Credit Suisse's Neutral and $36 target, BofA Merrill's Neutral and $34 target, and Citigroup's Buy and $37 target.

As you can see, based on the price targets, virtually no firms are really forecasting sharp gains for the stock over the next 12 months. But, again, this is more a function of the stock's significant opening pop versus the IPO price, rather than negative views regarding ELAN's business and fundamentals.

Not surprisingly, shares have opened weakly this morning, currently down about 2.5% to the $32 area. This is a key area for the stock because it opened for trading at $32.25 on its IPO day, putting all investors that did not get an IPO allocation potentially underwater. If buyers step in to support the stock here, despite the negative news regarding the initiations, that would be an encouraging development for the stock. On the flip side, a clear break below $32 could instigate a wave of selling as investors look to cut their losses.

Today, the quiet period for Eli Lilly spin-off Elanco Animal Health (ELAN 32.01, -0.57, -1.75%) expired, allowing firms involved with its IPO to
 
Add this to my Page Alerts.
MARKET PLACE
SPONSORED LINKS
 
  Follow Us On Linkedin  
 
 
LOGIN

CONTACT US
Support
Sitemap
PREMIUM SERVICES
Take a Tour
Compare Services
Request a Demo
INSTITUTIONAL SALES
ADVERTISING

CONTENT LICENSING

EMAILS & NEWSLETTERS
ABOUT US
Our Experts
Management Team

COMMUNITY
MEDIA
Events
News
Awards
PRIVACY STATEMENT
Cookie Policy
Reader Agreement
Policies
Disclaimer
Copyright © Briefing.com, Inc. All rights reserved.
Close
You must log in or register to access this area.
Tip of the Day
Virtual Url Page Popup